PMID- 27129795
OWN - NLM
STAT- MEDLINE
DCOM- 20170214
LR  - 20220318
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 49
IP  - 12
DP  - 2016 Aug
TI  - High BAX/BCL2 mRNA ratio predicts favorable prognosis in laryngeal squamous cell 
      carcinoma, particularly in patients with negative lymph nodes at the time of 
      diagnosis.
PG  - 890-6
LID - S0009-9120(16)30038-8 [pii]
LID - 10.1016/j.clinbiochem.2016.04.010 [doi]
AB  - OBJECTIVES: Laryngeal squamous cell carcinoma (LSCC), a common type of head and 
      neck cancer, is associated with high rates of metastasis and recurrence. 
      Therefore, accurate prognostic stratification of LSCC patients based on molecular 
      prognostic tumor biomarkers would definitely lead to a better clinical management 
      of this malignancy. The aim of this study was the investigation of the potential 
      combinatorial prognostic value of BCL2 and BAX mRNA expression in LSCC. DESIGN 
      AND METHODS: Total RNA was isolated from 105 cancerous laryngeal tissue specimens 
      obtained from patients having undergone surgical treatment for primary LSCC. 
      After cDNA preparation, a low-cost, in-house developed, sensitive and accurate 
      real-time quantitative PCR (qPCR) methodology was applied for the quantification 
      of BCL2 and BAX mRNA levels. Then, we carried out a biostatistical analysis to 
      assess the prognostic value of the BAX/BCL2 mRNA expression ratio. RESULTS: High 
      BAX/BCL2 mRNA expression constitutes a favorable prognosticator in LSCC, 
      predicting significantly longer disease-free survival (P=0.011) and overall 
      survival (P=0.014) of patients. More importantly, the significant prognostic 
      value of the BAX/BCL2 mRNA expression appeared to be independent of the 
      histological grade and size of the malignant laryngeal tumor as well as TNM 
      stage, as revealed by the multivariate bootstrap Cox regression analysis. 
      Kaplan-Meier survival analysis demonstrated also that the BAX/BCL2 ratio can 
      stratify node-negative (N0) LSCC patients into two subgroups with significantly 
      different DFS and OS (P=0.021 and P=0.009, respectively). CONCLUSIONS: The 
      BAX/BCL2 mRNA ratio is a putative molecular tissue biomarker in CLL and hence 
      deserves further validation in larger cohorts of LSCC patients.
CI  - Copyright (c) 2016 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Giotakis, Aris I
AU  - Giotakis AI
AD  - First Department of Otorhinolaryngology, Athens General Hospital "Hippokration", 
      National and Kapodistrian University of Athens, Athens GR-11527, Greece.
FAU - Kontos, Christos K
AU  - Kontos CK
AD  - Department of Biochemistry and Molecular Biology, National and Kapodistrian 
      University of Athens, Athens GR-15701, Greece.
FAU - Manolopoulos, Leonidas D
AU  - Manolopoulos LD
AD  - First Department of Otorhinolaryngology, Athens General Hospital "Hippokration", 
      National and Kapodistrian University of Athens, Athens GR-11527, Greece.
FAU - Sismanis, Aristides
AU  - Sismanis A
AD  - First Department of Otorhinolaryngology, Athens General Hospital "Hippokration", 
      National and Kapodistrian University of Athens, Athens GR-11527, Greece.
FAU - Konstadoulakis, Manousos M
AU  - Konstadoulakis MM
AD  - First Department of Propaedeutic Surgery, Athens General Hospital "Hippokration", 
      National and Kapodistrian University of Athens, Athens GR-11527, Greece.
FAU - Scorilas, Andreas
AU  - Scorilas A
AD  - Department of Biochemistry and Molecular Biology, National and Kapodistrian 
      University of Athens, Athens GR-15701, Greece. Electronic address: 
      ascorilas@biol.uoa.gr.
LA  - eng
PT  - Journal Article
DEP - 20160426
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (BAX protein, human)
RN  - 0 (BCL2 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (RNA, Messenger)
RN  - 0 (bcl-2-Associated X Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Squamous Cell/genetics/*pathology/surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*pathology/surgery
MH  - Lymph Nodes/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Rate
MH  - bcl-2-Associated X Protein/*genetics
OTO - NOTNLM
OT  - BCL2 family
OT  - Head and neck cancer
OT  - Molecular tumor biomarker
OT  - Oral cancer
OT  - Prognostic biomarker
OT  - Real-time quantitative PCR
EDAT- 2016/05/01 06:00
MHDA- 2017/02/15 06:00
CRDT- 2016/05/01 06:00
PHST- 2015/12/06 00:00 [received]
PHST- 2016/03/06 00:00 [revised]
PHST- 2016/04/22 00:00 [accepted]
PHST- 2016/05/01 06:00 [entrez]
PHST- 2016/05/01 06:00 [pubmed]
PHST- 2017/02/15 06:00 [medline]
AID - S0009-9120(16)30038-8 [pii]
AID - 10.1016/j.clinbiochem.2016.04.010 [doi]
PST - ppublish
SO  - Clin Biochem. 2016 Aug;49(12):890-6. doi: 10.1016/j.clinbiochem.2016.04.010. Epub 
      2016 Apr 26.